16 February 2024 in Aerosol Science and Technology
As SARS-CoV-2 swept across the globe, increased ventilation and implementation of air cleaning were emphasized by the US CDC and WHO as important strategies to reduce the risk of inhalation exposure to the virus. To assess whether higher ventilation and air cleaning rates lead to lower exposure risk to SARS-CoV-2, 1274 manuscripts published between April 2020 and September 2022 were screened using key words "airborne SARS-CoV-2 or "SARS-CoV-2 aerosol". Ninety-three studies involved air sampling at locations with known sources (hospitals and residences) were selected and associated data were compiled. Two metrics were used to assess exposure risk: SARS-CoV-2 concentration and SARS-CoV-2 detection rate in air samples. Locations were categorized by type (hospital or residence) and proximity to the sampling location housing the isolated/quarantined patient (primary or secondary). The results showed that hospital wards had lower airborne virus concentrations than residential isolation rooms. A negative correlation was found between airborne virus concentrations in primary-occupancy areas and air changes per hour (ACH). In hospital settings, sample positivity rates were significantly reduced in secondary-occupancy areas compared to primary-occupancy areas, but they were similar across sampling locations in residential settings. ACH and sample positivity rates were negatively correlated, though the effect was diminished when ACH values exceeded 8. While limitations associated with diverse sampling protocols exist, data considered by this meta-analysis support the notion that higher ACH may reduce exposure risks to the virus in ambient air.
3 October 2024 in Aerosol Science and Technology
Exposure to airborne respiratory viruses can be a health hazard in occupational settings. In this study, air sampling was conducted from January to March 2023 in two outpatient medical clinics—one primary care clinic and one clinic dedicated to the diagnosis and treatment of respiratory illnesses—for the purpose of assessing airborne respiratory virus presence. Work involved the operation of a BioSpot-VIVAS™ as a stationary air sampler and deployment of NIOSH BC-251 bioaerosol samplers as either stationary devices or personal air samplers worn by staff members. Results were correlated with deidentified clinical data from patient testing. Samples from seven days were analyzed for SARS-CoV-2, influenza A H1N1 and H3N2 viruses, and influenza B Victoria- and Yamagata-lineage viruses, with an overall 17.5% (17/97) positivity rate. Airborne viruses predominated in particles of aerodynamic diameters from 1–4 μm and were recovered in similar quantities from both clinics. BC-251 samplers (17.4%, 15/86) and VIVAS (18.2%, 2/11) collected detectable viruses at similar rates, but more numerous BC-251 samplers provided greater insight into virus presence across clinical spaces and job categories. 60% of samples from reception areas contained detectable virus, and exposure to significantly more virus (p = 0.0028) occurred at reception desks as compared to the “mobile” job categories of medical providers and nurses. Overall, this study provides valuable insights into the impacts of hazard mitigation controls tailored to reducing respiratory virus exposure and highlights the need for continued diligence toward exposure risk mitigation in outpatient medical clinics.
4 March 2026 in Aerosol Science and Technology
1. Atmospheric aerosols are a fundamental component of air pollution and have a significant impact on Earth’s climate and public health. Aerosols perturb the Earth’s climate system by scattering an...